SGLT2 inhibitors race to enter type-2 diabetes market.
Cormac
C
Sheridan
D000818:Animals; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D017277:Drug Approval / Q000191:economics; D055808:Drug Discovery / Q000191:economics; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000473:pathology; D040541:Marketing / Q000191:economics; D010695:Phlorhizin / Q000494:pharmacology / Q000627:therapeutic use; D051269:Sodium-Glucose Transporter 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D051297:Sodium-Glucose Transporter 2 / Q000378:metabolism; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D051269:Sodium-Glucose Transporter 1; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D010695:Phlorhizin